Top Page
MediPharm Labs
(TSX:LABS)
MediPharm Labs (LABS) vs. iShares MSCI Canada ETF (EWC)
MediPharm Labs Business Overview & Revenue Model
MediPharm Labs Earnings Call Summary
MediPharm Labs Financial Statement Overview
| Breakdown | TTM | Mar 2025 | Dec 2023 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 46.10M | 41.96M | 33.06M | 22.12M | 21.71M | 36.01M |
| Gross Profit | 13.47M | 12.80M | 5.86M | -1.91M | -15.25M | -43.98M |
| EBITDA | -6.13M | -7.52M | -10.48M | -27.09M | -38.55M | -53.40M |
| Net Income | -8.03M | -10.69M | -13.08M | -29.98M | -54.80M | -67.11M |
Balance Sheet | ||||||
| Total Assets | 46.60M | 53.73M | 63.94M | 65.50M | 92.36M | 118.23M |
| Cash, Cash Equivalents and Short-Term Investments | 10.58M | 11.69M | 17.98M | 24.14M | 34.11M | 19.91M |
| Total Debt | 423.00K | 388.00K | 2.29M | 632.00K | 216.00K | 18.46M |
| Total Liabilities | 8.74M | 10.55M | 10.93M | 9.49M | 9.21M | 39.82M |
| Stockholders Equity | 37.86M | 43.18M | 53.01M | 56.01M | 83.15M | 78.41M |
Cash Flow | ||||||
| Free Cash Flow | -7.15M | -5.01M | -12.81M | -16.93M | -14.00M | -45.28M |
| Operating Cash Flow | -7.01M | -4.86M | -12.34M | -16.07M | -13.21M | -37.77M |
| Investing Cash Flow | 4.58M | 413.00K | 6.87M | 5.16M | 35.00K | -7.45M |
| Financing Cash Flow | -79.00K | -1.85M | -368.00K | 796.00K | 27.80M | 26.42M |
MediPharm Labs Technical Analysis
MediPharm Labs Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | C$32.92M | 3.70 | 7.78% | ― | 28.55% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | C$10.09M | -2.86 | 11.57% | ― | -1.14% | ― | |
46 Neutral | C$23.88M | -5.08 | -77.67% | ― | 2.41% | 74.61% | |
46 Neutral | C$27.44M | -6.72 | -71.80% | ― | -3.94% | -17.62% | |
45 Neutral | C$29.45M | -3.68 | -19.10% | ― | 18.06% | 34.58% | |
44 Neutral | C$7.69M | 5.19 | ― | ― | 15.64% | 58.47% |
MediPharm Labs Corporate Events
MediPharm Labs announced a leadership transition, with Chief Executive Officer David Pidduck stepping down effective January 23, 2026, while remaining on the board, and Chief Financial Officer Greg Hunter taking on the role of interim CEO while retaining his CFO responsibilities. The board highlighted Pidduck’s role in restructuring the business, improving profitability and integrating the VIVO Cannabis acquisition, and emphasized Hunter’s track record in cost reduction, financial and operational controls, and commercial strategy, noting that his broad experience at major global healthcare companies positions him to maintain operational discipline and support the company’s growth and competitive positioning during the transition period.
The most recent analyst rating on (TSE:LABS) stock is a Hold with a C$0.07 price target. To see the full list of analyst forecasts on MediPharm Labs stock, see the TSE:LABS Stock Forecast page.
MediPharm Labs has signed a definitive supply agreement with Remidose Aerosols’ Costa Rican affiliate, Remidose LATAM, to export a portfolio of GMP-certified medicinal cannabis products—including oils, tinctures, metered dose inhalers and dried flower—into Costa Rica’s newly opened medical cannabis market. The deal positions MediPharm to tap into a regulated market projected to exceed US$35 million annually, reinforcing its strategy of leveraging its regulatory expertise and pharmaceutical-grade production standards to expand in highly controlled international jurisdictions while enabling Remidose LATAM to offer Costa Rican patients access to globally sourced, high-quality cannabis therapies.
The most recent analyst rating on (TSE:LABS) stock is a Hold with a C$0.06 price target. To see the full list of analyst forecasts on MediPharm Labs stock, see the TSE:LABS Stock Forecast page.
MediPharm Labs is positioning itself to capitalize on the U.S. decision to reclassify cannabis from Schedule I to Schedule III, a move that recognizes its medical use and removes major barriers to clinical research. With FDA site registration, a Drug Establishment License, an FDA-inspected facility and a track record of supplying products for more than 10 clinical trials, including NIH-funded U.S. studies, the company argues it has a competitive edge among publicly listed cannabis-focused firms. The rescheduling is expected to accelerate demand for compliant, standardized cannabis APIs in U.S. clinical trials and could eventually support federally sanctioned medical access programs, potentially boosting MediPharm’s U.S. partnerships and revenue opportunities. The company also notes that the change may open the door to greater institutional pharma and biotech investment in research-oriented cannabis companies, enhancing access to capital for its growth plans.
The most recent analyst rating on (TSE:LABS) stock is a Hold with a C$0.06 price target. To see the full list of analyst forecasts on MediPharm Labs stock, see the TSE:LABS Stock Forecast page.
MediPharm Labs announced changes to its Board of Directors, with Shelley Potts stepping down and Michael Bumby rejoining the board. Bumby’s extensive experience in finance and governance, particularly in the cannabis and pharmaceutical sectors, is expected to support MediPharm’s strategic priorities and advancement in pharmaceutical cannabinoids. This move is significant for the company as it continues to strengthen its position in the cannabinoid industry, following its acquisition of VIVO Cannabis Inc. in 2023, which expanded its reach in Canada, Australia, and Germany.
The most recent analyst rating on (TSE:LABS) stock is a Hold with a C$0.06 price target. To see the full list of analyst forecasts on MediPharm Labs stock, see the TSE:LABS Stock Forecast page.
MediPharm Labs has completed its first shipment to France, marking a significant milestone in its expansion into the European medicinal cannabis market. This achievement highlights the company’s capability to meet stringent European standards and strengthens its position as a trusted supplier of pharmaceutical-grade cannabis products. The French market is expected to grow significantly, and MediPharm’s strategic partnerships and global distribution network position it well to capitalize on this growth. As of Q3 2025, international medical cannabis accounted for 56% of the company’s revenue, demonstrating its successful global expansion.
MediPharm Labs announced the complete dismissal of a defamation action initiated by Apollo, Nobul, and Regan McGee under Ontario’s anti-SLAPP law. The Superior Court of Justice in Ontario dismissed the $50 million claim against MediPharm’s executives, citing a lack of evidence from the plaintiffs. This legal victory follows previous dismissals of related claims and applications against the company, reinforcing MediPharm’s legal standing and potentially strengthening its position in the industry. Additionally, MediPharm is addressing unauthorized press releases related to Apollo that were disseminated without its consent.
MediPharm Labs reported a successful Q3 2025 with a 17% increase in revenue compared to Q3 2024, driven by significant gains in international medical cannabis sales, which now account for 56% of total revenue. The company also achieved a notable 19% reduction in operating expenses year-over-year, reflecting its commitment to disciplined cost management and sustainable growth, while maintaining a strong cash balance of $10.6 million.
MediPharm Labs announced it will release its third quarter 2025 financial results on November 13, 2025, before markets open. The company will also host a conference call and webcast to discuss these results. This announcement is significant as it reflects MediPharm’s ongoing commitment to transparency and engagement with stakeholders, and it may impact the company’s market positioning and investor relations.